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Abstract
Background: A new virus called the Merkel Cell Polyomavirus (MCPyV) has recently been found in Merkel Cell Carcinoma
(MCC). MCC is a rare aggressive small cell neuroendocrine carcinoma primarily derived from the skin, morphologically
indistinguishable from small cell lung carcinoma (SCLC). So far the actual presence of the virus in MCC tumour cells on a
morphological level has not been demonstrated, and the presence of MCPyV in other small cell neuroendocrine carcinomas
has not been studied yet.
Methodology/Principal Findings: We investigated MCC tissue samples from five patients and SCLCs from ten patients for
the presence of MCPyV-DNA by PCR and sequencing. Electron microscopy was used to search ultrastructurally for
morphological presence of the virus in MCPyV-DNA positive samples. MCPyV was detected in two out of five primary MCCs.
In one MCC patient MCPyV-DNA was detected in the primary tumour as well as in the metastasis, strongly suggesting
integration of MCPyV in the cellular DNA of the tumour in this patient. In the primary MCC of another patient viral particles
in tumour cell nuclei and cytoplasm were identified by electron microscopy, indicating active viral replication in the tumour
cells. In none of the SCLCs MCPyV-DNA was detected.
Conclusions/Significance: Our results strongly suggest that MCPyV is an oncogenic polyomavirus in humans, and is
potentially causally related to the development of MCC but not to the morphological similar SCLC.
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Introduction
Merkel Cell Carcinoma (MCC) is a rare carcinoma of the skin
that metastasizes quickly and has a 5-year mortality rate as high as
50% [1]. The incidence is dramatically increasing and has tripled
in the past 15 years in the U.S. [2]. Factors implicated in the
etiology are ultraviolet exposure, advanced age and immunosup-
pression [2]. In particular, many forms of T-lymphocyte immune
suppression are linked to MCC, e.g. AIDS [3], solid organ
transplantation [4] and chronic lymphocytic leukaemia [5].
In 2008 Feng et al. discovered a new polyomavirus in MCC tissue
samples [6], and called it the Merkel cell polyomavirus (MCPyV).
The family of Polyoma viruses is subdivided into several genetically
distinct groups. One of these groups, the SV40 subgroup, contains
the four known human Polyoma viruses: BK, JC, KI and WU. BK
and JC virus are known to cause infections in immunocompromised
patients, while KI and WU were isolated from nasopharyngeal
secretions of patients with respiratory infections [7–9]. Polyoma-
viruses can be oncogenic in animals, but until now, no polyomavirus
has been proven to be oncogenic in humans [10].
Feng et al. showed that the MCPyV is integrated at different
locations within the human genome in the MCC, and furthermore
that the large T antigen transcript is expressed in MCC [6]. This
implicates that MCPyV is not only associated with MCC, but that
it might in fact be the causative agent. Indeed, several studies have
reported the presence of MCPyV-DNA in 43–85% of MCC cases
[6,11–13].
MCC and small cell lung carcinoma (SCLC) are both aggressive
neuroendocrine carcinomas, histologically composed of morpho-
logically identical small cells. In fact, MCC is often referred to as
the cutaneous form of small cell lung carcinoma [14]. Like MCC,
SCLC also is a highly malignant carcinoma with a 5-year survival
rate lower than 5% [15]. This tumour comprises about 10–20% of
the lung cancers and is strongly related to tobacco usage [15,16].
To investigate the incidence of MCPyV and the relation to
oncogenesis, tissue samples from small cell neuroendocrine
carcinomas from both skin and lung were analyzed for the
presence of MCPyV-DNA. We found that MCPyV-DNA was
present in 40% of the MCC cases, and was absent in all SCLCs.
This suggests that MCPyV has a restricted tropism. MCPyV-DNA
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patient, indicating viral DNA integration. Furthermore, we
studied MCC tissue samples by electron microscopy in order to
determine the actual presence of viral particles in the tumour cells.
MCPyV viral particles were ultrastructurally identified in primary
MCC tumour cell cytoplasm and nuclei in one patient, strongly
suggesting active viral replication.
Materials and Methods
Patients and tissues
We obtained frozen and paraffin-embedded (formalin fixed)
MCC and SCLC biopsy and resection samples from the archives
of the Pathology department of the Radboud University Nijmegen
Medical Centre. All samples were collected for diagnostic purposes
in the years 1995–2008. From five MCC patients seven samples
were used, including two primary MCCs and their metastases.
Frozen SCLC samples from ten patients were used, representing
three primary tumours, three nodal and four distant metastases. In
all cases the diagnosis of either MCC or SCLC was confirmed with
immunohistochemistry using thyroid transcription factor-I and
low-molecular weight cytokeratin 20 in order to distinguish
between the two entities. For PCR, control specimens consisting
of frozen and paraffin-embedded tissue samples from eight
patients with variable malignant and benign skin diseases were
used. The clinical characteristics of all patients are listed in Table 1.
DNA isolation
The paraffin embedded sections were incubated overnight with
Proteinase K in lysis buffer (56uC) before DNA was isolated using
the EZ1 DNA Tissue Kit (Qiagen Benelux BV) as described
previously [17]. The DNA was isolated from the frozen tissue
sections by using Magnapure Total NA isolation kit (Roche
Molecular Diagnostics). The isolation product was stored at
280uC until used for PCR.
PCR and sequence analysis
For PCR, 4 mm sections were used of the paraffin embedded
tissue, and 10 mm sections of the frozen tissue samples. All samples
were prepared and analyzed under sterile conditions. All tissue
samples were studied in accordance with national ethical
principles.
Before MCPyV-DNA detection, the quality of the DNA was
tested by b-globin PCR for human DNA detection (Roche
Table 1. Patient Characteristics.
Patient ID Gender Age Location Immunosuppressed Diameter (mm) Solar elastosis
Merkel Cell Carcinoma
1 f 72 Facial skin No 6 Yes
2 m 56 Tongue No 12 No
3a m 74 Facial skin No 15 Yes
3b Metastasis skin lower leg unknown
4 f 65 Facial skin No 13 Yes
5a m 47 Facial skin Renal transplant .50 Yes
5b Liver metastasis
Small Cell Lung Carcinoma
1 f 55 Mediastinal metastasis No
2 f 72 Intrapulmonary No
3 m 59 Cerebral metastasis No
4 f 40 Mediastinal metastasis No
5 m 62 Lymph node metastasis No
6 m 58 Cerebral metastasis No
7 f 67 Hepatic metastasis No
8 f 48 Intrapulmonary No
9 m 63 Intrapulmonary No
10 m 64 Cerebral metastasis No
Control patients (skin lesions) Type of lesion
1 m 62 Face No Basal cell carcinoma
2 m 55 Face No Verruca seborrhoica
3 f 37 Mamma No Dermal naevus
4 m 54 Digit Renal transplant Squamous cell carcinoma
5 f 69 Leg No Psoriasiform dermatitis
6 m 63 Hand No Spongiotic dermatitis
7 f 66 Back No Porphyria
8 f 45 Presternal No Dermal naevus
f: female; m: male.
doi:10.1371/journal.pone.0004958.t001
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detection were adapted from Feng et al. [6]. We used LT3 as this
primer set was reported to have the highest sensitivity [13]. We
decreased the size of the amplicons to 250 bp to obtain higher
sensitivities in paraffine processed tissue samples [18]. The forward
primer sequence was 59-atc tgc acc ttt tct aga ctc c-39, and the
reverse primer sequence 59-ata tag ggg cct cgt caa cc-39. The
MCPyV PCR was performed using PCR Mastermix (Roche
Diagnostics), containing Taq DNA Polymerase. Five mL of DNA
was used in a total volume of 45 mL. Water instead of DNA
template was used for PCR-negative controls containing all other
PCR components. The PCR consisted of 40 cycles with an
annealing temperature of 50uC. The PCR products were analyzed
by gel electrophoresis, and by sequence analysis.
The MCPyV positive samples were sequenced using the Big
Dye Terminator v3.1 Cycle Sequence (Applied Biosystems). The
obtained sequences were compared with the reference sequence of
the National Center for Biotechnology Information (NCBI) Entrez
Nucleotide database (gb/EU375803.1 Merkel cell polyomavirus
isolate MCC350 and gb/EU375804.1 Merkel cell polyomavirus
isolate MCC339), using the NCBI blast program. Confirmed
positive samples were later used as positive controls in subsequent
PCR experiments.
Electron microscopy
For electron microscopy a piece of paraffin embedded material
from two MCPyV positive primary MCC samples was used. The
material was deparaffinised overnight in xylene, rehydrated and
washed in 0.1 M sodium cacodylate buffer. The tissue fragments
were postfixed in palade-buffered 2% OsO4 for 1 h, dehydrated,
and embedded in Epon812, Luft’s procedure (Merck, Darmstadt,
Germany). Ultrathin sections were contrasted with 4% uranyl
acetate for 45 min and subsequently with lead citrate for 5 min at
room temperature. Sections were examined in a Jeol 1200 EX2
electron microscope (JEOL, Tokyo, Japan).
Ethics statement. The tissue samples were originally taken
for diagnostic purposes. For our research we selected the
remainder of tissue samples from our archive after which they
were encoded. Our hospital uses the policy that encoded patient
material that was originally removed for diagnostic purposes may
be used for further research unless the patient has stated otherwise.
In case of research with encoded/anonymous material informed
consent is not required, as long as the researcher is not able to
discover the patients identity linked to the research material.
When a patient has explicitly refused, it is not allowed to use these
tissue samples for research. The authors state that they used
encoded tumor samples, and that none of the patients explicitly
refused to participate in research.
The researchers did not consult an ethics committee/IRB prior
too the research.
Results
The mean age of MCC patients was 63 years and 60% were
male. MCPyV-DNA was detected in the primary tumours of two
out of five MCC patients (40%). Of these two patients one had
metastatic cancer, and MCPyV-DNA was detected in this
metastasis as well (patient no. 3). The other three primary MCC
samples and the metastasis of the other metastasised patient, were
all tested negative for MCPyV-DNA. Sequencing of all positive
PCR products showed MCPyV-DNA.
In order to morphologically establish the presence of the virus in
MCPyV-DNA positive samples electron microscopy was per-
formed. Glutaraldehyde is the preferred fixative for electron
microscopy. Unfortunately, there was only formalin fixed and
paraffin embedded or frozen tissue (without cryoprotection) of
MCC present in our archive. These conventional fixation and
embedding methods are known to cause various ultrastructural
artefacts depending upon several parameters [19]. Due to these
artefacts suboptimal morphology was obtained and only one of the
MCC samples could be used for ultrastructural investigation
(patient no. 4). Electron microscopy of this sample revealed both
intranuclear and intracytoplasmic viral particles. The viral
particles were stained by electrondense reaction products and
measured approximately 50 nm, being compatible with viral
polyoma particles. Nuclear localization of loose viral particles,
penetration through the nuclear membrane and intracytoplasmic
accumulation of capsids was visualized (Figure 1).
Figure 1. Electron micrographs showing viral particles in a sample of patient no. 4. a) destroyed merkel cell carcinoma cell with viral
particles (white arrow) measuring 50 nm, mingled with nuclear fragments and multiple smaller ribosomes (20 nm). b) penetration of virions through
the nuclear membrane (white arrows) toward the cytoplasm (on the left). (original magnification; 120006).
doi:10.1371/journal.pone.0004958.g001
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male. The ten SCLC samples were tested for MCPyV-DNA using
the LT3 primer set and all tested negative.
The control patients had a mean age of 56 and 50% were male.
Of the eight control tissue samples from different patients, none
tested positive by MCPyV-DNA PCR.
Discussion
In this study we provide evidence that only small cell
neuroendocrine carcinomas from the skin and not from the lung
contain MCPyV-DNA. This suggests that MCPyV has a restricted
tropism. MCPyV-DNA was found in the primary and the
metastatic tumour of one patient suggesting viral DNA integration.
The ultrastructural identification of MCVyP viral particles in
primary MCC tumour cell cytoplasm and nuclei in another
patient, suggests active viral replication.
In our small patient group we found 40% of the MCC patients
positive for MCPyV-DNA, which is more or less similar to data
reported in previous studies (43–85%) [6,11–13]. As the viral
DNA seems to be able to integrate into the host genome, as was
evidenced by Feng et al. and suggested by us, based on our finding
of the MCPyV positive metastasis in one patient, a causal
relationship between MCPyV infection and the development of
MCC is realistic. However until now, on average, only half of the
MCC patient populations studied are MCPyV-DNA positive.
MCPyV is a member of the polyomavirus group, belonging to the
family of the Papovaviridae. Another member of this family are
the papillomaviruses and some intriguing similarities between the
human papillomaviruses (HPV) and MCPyV may explain the
relatively low prevalence of MCPyV in MCC.
First of all the causal relationship between HPV and the
development of cervical cancer has been proven [20] and the
integration of the HPV-DNA into the host genome is the main
feature of oncogenesis. In parallel to our demonstration of
MCPyV-DNA in MCC metastases, HPV-DNA has been detected
in the metastases of HPV positive invasive cervical carcinomas as
well [21]. Furthermore, about 60% of the cervical cancers are
positive for HPV 16, the remaining cancers are caused by a broad
variety of at least 12 other HPV genotypes [22]. In accordance
with cervical carcinoma, the MCCs that tested negative for
MCPyV may be caused by other, yet unidentified, MCPyV
genotypes, not detected by the specific primer set used in studies so
far. This might also explain the much higher proportion of
MCPyV positive MCC tumours found in North American patients
(43%) compared to Australian patients (24%) [12].
On the other hand this difference could also be due to higher
sun exposure in the Australian population. Sun-exposure is an
etiological factor in MCC, as evidenced by the finding of UV-
related mutations in for instance TP53 in MCC, and clinical
association of MCC with other non-melanoma skin cancers
[23,24].
The 40 to 85% range in MCPyV positive MCC may also be
explained by the existence of two different but parallel oncogenic
pathways, one MCPyV related and one MCPyV non-related
pathway. A similar theory of two separate pathways leading to
vulvar carcinoma, involving the polyomaviruses-related human
papillomaviruses has been suggested.
First, a human papillomavirus (HPV)-dependent pathway, in
which premalignant stages of vulvar cancer are the classic vulvar
intraepithelial neoplasia (VIN) lesions. Second, an HPV-indepen-
dent pathway, associated with differentiated VIN III lesions and/
or lichen sclerosus [25].
In SCLC, although morphologically almost indistinguishable
from MCC, both consisting of small cells with neuroendocrine
features and both showing an aggressive behaviour, no MCPyV-
DNA could be detected. However, although unlikely, the
possibility of unknown strains of MCPyV related to SCLC cannot
be ruled out completely.
We are the first to demonstrate the actual presence of the
MCPyV within the MCC tumour cell nuclei and cytoplasm
morphologically by using electron microscopy. The finding of
multiple particles, in the cytoplasm as well as in the nuclei, suggests
active viral replication. It demonstrates MCPyV viral particles to
be present in MCC tumour cells. Unfortunately, due to fixation of
the processed materials, electron microscopy could only be
performed on one primary MCC in our study.
In conclusion, we found MCPyV-DNA in 40% of the MCCs
and in the metastasis of one patient. MCPyV was found both in an
integrated form and, as viral particles as evidenced by electron
microscopy in another patient. In the morphological similar
SCLC, MCPyV-DNA could not be detected which either suggests
a different oncogenic pathway or the existence of yet unidentified
MCPyV genotypes. When transforming and immortalizing
properties of MCPyV are demonstrated, this will ultimately prove
its carcinogenic nature in humans.
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